Is Scar Tissue a Hit or Flop? Official Box Office Record & Profit Analysis
The official verdict is out. With a worldwide gross of $30M, Scar Tissue is declared a Disaster.
📊 Box Office Snapshot
📔 Detailed Verdict Analysis
📜 Detailed Financial Report
Scar Tissue, released in 2017, entered the cinematic marketplace as a highly anticipated release. The production path for this project involved significant capital, with a reported budget of approximately $50M. In the modern film economy, recovering such an investment requires a multifaceted theatrical strategy spanning domestic and international territories.
📈 Collection Trajectory
The box office journey for Scar Tissue has culminated in a worldwide gross of approximately $30M. This figure represents the total theatrical footprint, reflecting a Return on Investment (ROI) of -40%. The underwhelming numbers suggest a disconnect with the intended audience, limiting the film's potential for a long theatrical life.
⚖️ Profitability & Verdict
Analyzing the multiplier effect and market sentiment, Scar Tissue navigated the competitive landscape with an audience reception score of 1/10. When weighing the production costs against the global returns, Scar Tissue is effectively categorized as a Disaster. The outcome highlights the risks involved in big-budget filmmaking when audience alignment is missed.
🔍 Comparables
In the context of other contemporary releases, the performance of Scar Tissue will likely influence how studios approach similar projects in the future. Whether through its innovative visual style or its narrative choices, the film's financial footprint remains a key piece of the 2017 box office narrative.